Remi Barbier, Cassava CEO

Alzheimer's biotech comes un­der at­tack as pe­ti­tion calls for tri­al halt, da­ta au­dit — and it's fight­ing back

Lit­tle Cas­sa­va Sci­ences has com­plete faith in its ex­per­i­men­tal Alzheimer’s drug. Ever since piv­ot­ing away from a four-time re­ject anal­gesic (and from its for­mer iden­ti­ty as Pain Ther­a­peu­tics), the biotech has plowed steadi­ly away at clin­i­cal tri­als for a new lead pro­gram called simu­fil­am, plot­ting ma­jor Phase III tri­als and sig­nif­i­cant in­vest­ment in­to the neu­rode­gen­er­a­tive dis­ease — even be­fore the FDA ap­proval of Bio­gen’s Aduhelm rein­vig­o­rat­ed the en­tire field.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.